STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately
The insurance portfolio of the
The profit impact from the transfer of the insurance portfolio is not included in Orion’s outlook for 2023 which remains unchanged.
President and CEO | SVP, Corporate Functions |
Contact person:
tel. +358 10 426 2721
Publisher:
Communications
Orionintie 1A, FI-02200
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to
![](https://ml-eu.globenewswire.com/media/ZmUzMTk3YTktZWIwYy00ZTJlLWE2N2EtYTVkZWYyOTlmMDAyLTEwMTM1MzY=/tiny/Orion-Oyj.png)
© OMX, source